5 news items
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
with DAXXIFY®, roughly 50% of peak efficacy remained at the time of their request. In the ASPEN-OLS 52-week long-term follow-up study, approximately 60
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
efficacy remained at the time of their request. In the ASPEN-OLS 52-week long-term follow-up study, approximately 60% of retreatments were at 16 weeks
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AADI
AIMD
AKRO
4 Mar 24
. (NASDAQ:AADI) shares surged 8.8% to $2.0899 after the company announced publication of long-term efficacy and safety data further supporting
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
ACMR
ADSE
BYND
4 Mar 24
% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy
Earnings Outlook For Revance Therapeutics
RVNC
27 Feb 24
52-week period, shares are down 82.36%. Given that these returns are generally negative, long-term shareholders are likely unhappy going
- Prev
- 1
- Next